#PlantBased #Stock Endexx's (OTCBB: $EDXC) HYLA Reports Orders Exceeding
200,000 units for #ZeroNicotine #Vape @EndexxCorp
CAVE
CREEK, Ariz., September 28, 2022 ––(Investorideas.com Newswire) Endexx Corporation (OTCBB:EDXC), a provider of innovative, plant-based, and
sustainable health and skincare products, today announces that its recently
acquired (controlling-interest) HYLA division, secured two major purchase
orders for its new innovative
vape-delivery product that holds 4500 puffs per built
in
cartridge unit.
Read this news,
featuring EDXC in full at https://www.investorideas.com/news/2022/lohas/09281EDXC-Zero-%20Nicotine-Vape.asp
Combined,
the orders represent a 150,000-unit order and a 52,000-unit order for over
200,000 units within the first month of the acquisition of Hyla. The newly
innovated “No-Nic” (zero- nicotine) vape product produced by HYLA offers 4500
puffs per disposable unit. This expanded puff capacity far exceeds the capacity
of its competitor’s products worldwide. Formulating with Guarana and Levodopa,
this product is forecasted to replace the recently banned nicotine products
sold internationally where vape products are available.
Todd
Davis, CEO of Endexx, stated “HYLA’s new product line fills a major gap created
by the banning of flavored nicotine vape products. We believe plant-derived
products are the alternative and the solution that meets market demands today.
The two purchase orders came from prominent distributors in the West Coast
region of the US and a large western region in Asia. These orders expand both
our international and domestic distribution networks helping to expedite our
growth initiatives.”
About
Hyla
Hyla develops and distributes zero-nicotine
plant-powered, vape-delivered products made with vegan formulations and
functional plant extract ingredients. Hyla harnesses the power of Guarana and
Levodopa to create plant-derived high-performance botanical products. For more
information: www.tryHyla.com
About
Endexx Corporation
Endexx
Corporation develops and distributes all natural, plant-derived topical
skincare products. Its products vary
from balms, creams, lotions, butters, masks, scrubs, and oils, all with the
shared purpose of healthy skin and grooming wellness. The science behind these products involves a
decade of clinical research in the field and lab work to provide functional
formulation with ingredients for optimal absorption and support of skin health.
www.endexx.com
Safe
Harbor Statement Under the Private Securities Litigation Reform Act of 1995
We
caution that any forward-looking statements (as such term is defined in the
U.S. Private Securities Litigation Reform Act of 1995) contained in this press
release or made by us, our management, or our spokespeople involve risks and
uncertainties and are subject to change based on various factors, many of which
are beyond our control. Accordingly, our future performance and financial
results may differ materially from those expressed or implied in any such
forward-looking statements. Forward-looking statements include, without
limitation, statements regarding our future operating results, the
implementation and impact of our strategic plans, and our ability to meet
environmental, social, and governance goals. Words such as “estimate,”
“commit,” “target,” “goal,” “project,” “plan,” “believe,” “seek,” “strive,”
“expect,” “anticipate,” “intend,” “potential” and any similar expressions may
identify forward-looking statements. Risks associated with the following
factors, among others, could affect our financial performance and cause actual
results to differ materially from those expressed or implied in any
forward-looking statements:
Except
as may be required by law, we assume no obligation and do not intend to make
publicly available any update or other revisions to any of the forward-looking
statements contained in this press release to reflect circumstances existing
after the date of this press release or to reflect the occurrence of future
events, even if experience or future events make it clear that any expected
results expressed or implied by those forward-looking statements will not be
realized. More information on potential factors that could affect our results
is included “Risk Factors” in our Annual Report on Form 10-K filed with the
Securities and Exchange Commission on March 31, 2022.
For
further information, please contact:
Endexx Corporation
Endexx@endexx.com
480-595-6900
Investors:
Scott
Arnold
CORE
IR
Media:
Jules
Abraham
CORE IR
917-885-7378
Paid News -Disclaimer/Disclosure: Investorideas.com is a digital publisher of third
party sourced news, articles and equity research as well as creates original
content, including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers.
Disclosure : this news release featuring Endexx Corporation is a paid for service
on Investorideas.com More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and
our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Please read
Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
About Investorideas.com
https://www.investorideas.com/About/
Sign up for free stock news alerts at Investorideas.com
https://www.investorideas.com/Resources/Newsletter.asp
No comments:
Post a Comment